BT8009 monotherapy in enfortumab vedotin (EV)-naive patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1

被引：1
|
作者：
Reig Torras, O. [1 ]
Crouzet, L. [2 ]
Necchi, A. [3 ,4 ]
Baldini, C. [5 ]
Lostes Bardaji, M. J. [6 ,7 ]
Doger de Speville, B. [8 ]
Italiano, A. [9 ,10 ]
Verlingue, L. [11 ]
Boni, V. [12 ]
Carter, L. [13 ,14 ]
Duran, I. [15 ]
Garmezy, B. [16 ]
Galsky, M. D. [17 ]
Falchook, G. S. [18 ]
DeMars, L. [19 ]
Josephs, K. [20 ]
Xu, C. [21 ]
Bader, J. [22 ]
Fontana, E. [23 ]
机构：
[1] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
[2] Ctr Eugene Marquis, UNICANCER, Rennes, France
[3] Univ Vita Salute San Raffaele, Dept Med Oncol, Milan, Italy
[4] IRCCS Osped San Raffaele, Dept Med Oncol, Milan, Italy
[5] Gustave Roussy Canc Campus, Drug Dev Dept DITEP, Villejuif, France
[6] Vall DHebron Univ Hosp, Oncol Dept, Barcelona, Spain
[7] Vall dHebron Inst Oncol, Oncol Dept, Barcelona, Spain
[8] START Madrid FJD Hosp Univ Fdn Jimenez Diaz, Start Madrid Phase Unit 1, Madrid, Spain
[9] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France
[10] Univ Bordeaux, Bordeaux, France
[11] Ctr Leon Berard, Phase Clin Unit 1, Lyon, France
[12] NEXT Madrid, Univers Hosp Quiron Salud Madrid, Madrid, Spain
[13] Univ Manchester, Med Oncol, Manchester, Lancs, England
[14] Christie NHS Fdn Trust, Manchester, Lancs, England
[15] Hosp Univ Marques de Valdecilla IDIVAL, Dept Despacho 271, Santander, Spain
[16] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA
[17] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA
[18] HealthONE, Sarah Cannon Res Inst, Med Oncol, Denver, CO USA
[19] Bicycle Therapeut, Clin Dev, Cambridge, MA USA
[20] Bicycle Therapeut, Clin Sci, Cambridge, MA USA
[21] Bicycle Therapeut, Biostat, Cambridge, MA USA
[22] Bicycle Therapeut, Quantitat Pharmacol, Cambridge, MA USA
[23] Sarah Cannon Res Inst UK, Drug Dev, London, England
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.718
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
652P
引用
收藏
页码：S515 / S516
页数：2
相关论文
共 50 条
  • [21] Enfortumab vedotin (EV) as monotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of stage I of a phase 2 trial.
    Swami, Umang
    Maughan, Benjamin L.
    Boucher, Kenneth M.
    Nordblad, Blake
    Lloyd, Jennifer
    Batten, Julia
    Phunrab, Tenzin Kunsang
    Quertinmont, Joshua
    Kohli, Manish
    Gupta, Sumati
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL)
  • [22] Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma
    Rosenberg, Jonathan E.
    Flaig, Thomas W.
    Friedlander, Terence W.
    Milowsky, Matthew I.
    Srinivas, Sandy
    Petrylak, Daniel Peter
    Merchan, Jaime R.
    Bilen, Mehmet Asim
    Carret, Anne-Sophie
    Yuan, Nancy
    Sasse, Carolyn
    Hoimes, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [23] Updated interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma
    Brown, Jacqueline T.
    Nazha, Bassel
    Liu, Yuan
    Lozada, Kelsea
    Smith, Jeremy D.
    Hartman, Caitlin
    McClintock, Greta Russler
    Kucuk, Omer
    Carthon, Bradley Curtis
    Harvey, R. Donald
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naive UC (DAD-IO)
    McGregor, Bradley Alexander
    Kwak, Lucia
    Sonpavde, Guru P.
    Berg, Stephanie A.
    Choueiri, Toni K.
    Bellmunt, Joaquim
    Mantia, Charlene
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Real world toxicity profile of enfortumab vedotin (EV) with or without pembrolizumab (P) in ultra elderly urothelial carcinoma (UC) patients (pts).
    Mar, Nataliya
    Go, Jeanah
    Cabral, Marsenne Y.
    Kaakour, Dalia
    Dwabe, Sami
    Seyedin, Steven Neema
    Drakaki, Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [26] Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC).
    Koshkin, Vadim S.
    Henderson, Nicholas
    Kilari, Deepak
    Jindal, Tanya
    Alhalabi, Omar
    Freeman, Dory
    Basu, Arnab
    Barata, Pedro C.
    Bilen, Mehmet Asim
    Zakharia, Yousef
    Emamekhoo, Hamid
    Shah, Sumit
    Milowsky, Matthew I.
    Davis, Nancy B.
    Gupta, Shilpa
    Hoimes, Christopher J.
    Grivas, Petros
    Bellmunt, Joaquim
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [27] Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
    Jindal, Tanya
    Zhang, Li
    Jiang, Cindy
    Kilari, Deepak
    Alhalabi, Omar
    Nizam, Amanda
    Basu, Arnab
    Bilen, Mehmet Asim
    Zakharia, Yousef
    Milowsky, Matthew I.
    Shah, Sumit
    Hoimes, Christopher J.
    Davis, Nancy B.
    Gupta, Shilpa
    Emamekhoo, Hamid
    Grivas, Petros
    Bellmunt, Joaquim
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in ≥ second line in metastatic urothelial carcinoma (mUC)
    McGregor, B. A.
    Sonpavde, G. P.
    Kwak, L.
    Gao, X.
    Berg, S.
    Mantia, C.
    Wei, X. X.
    Ravi, P.
    Michaelson, M. D.
    Choueiri, T. K.
    Bellmunt, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1153 - S1154
  • [29] EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
    Petrylak, Daniel Peter
    Balar, Arjun Vasant
    O'Donnell, Peter H.
    McGregor, Bradley Alexander
    Heath, Elisabeth I.
    Yu, Evan Y.
    Galsky, Matt D.
    Hahn, Noah M.
    Gartner, Elaina M.
    Pinelli, Juan
    Melhem-Bertrandt, Amal
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
  • [30] Study EV-103: Update on durability results and long term outcome of enfortumab vedotin plus pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).
    Friedlander, Terence W.
    Milowsky, Matthew I.
    Bilen, Mehmet Asim
    Srinivas, Sandy
    Mckay, Rana R.
    Flaig, Thomas W.
    Hoimes, Christopher J.
    Balar, Arjun Vasant
    Henry, Elizabeth
    Petrylak, Daniel P.
    Sasse, Carolyn
    Kataria, Ritesh S.
    Yu, Yao
    Carret, Anne-Sophie
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345